-
公开(公告)号：US09211258B2
公开(公告)日：2015-12-15
申请号：US13583769
申请日：2011-03-09
IPC分类号： A61K31/44 , A61K9/10 , A61K31/428
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
摘要翻译： 包含分散在悬浮液中的利福昔明和一种或多种药学上可接受的添加剂的稳定的，掩味的即用型悬浮液。 还提供了制备利福昔明的稳定的，掩味的即用型悬浮液的方法，包括以下步骤：将利福昔明与悬浮液基体混合，并通过研磨悬浮液进一步调节利福昔明颗粒，获得均匀分散的利福昔明悬浮液 。
-
公开(公告)号：US20160136141A1
公开(公告)日：2016-05-19
申请号：US14937730
申请日：2015-11-10
IPC分类号： A61K31/437
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
-
公开(公告)号：US20120214833A1
公开(公告)日：2012-08-23
申请号：US13503733
申请日：2010-10-27
IPC分类号： A61K31/437 , A61P31/00
CPC分类号： A61K31/437 , A61K9/0043 , A61K9/0046 , A61K9/0056 , A61K9/10 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K9/2086 , A61K47/10 , A61K47/32 , Y02A50/473
摘要： A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.
摘要翻译： 利福昔明的固体分散体，其包含利福昔明和药学上可接受的载体。 包含利福昔明的固体分散体的药物组合物。
-
4.发明申请CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR 审中-公开选择性硒激酶抑制剂的控制释放药物组合物公开(公告)号：US20140010883A1
公开(公告)日：2014-01-09
申请号：US14005613
申请日：2012-03-16
IPC分类号： A61K9/50 , A61K31/4525
CPC分类号： A61K9/50 , A61K9/2086 , A61K9/209 , A61K9/2846 , A61K31/4525
摘要： The present invention provides a controlled release pharmaceutical composition comprising selective serotonin reuptake inhibitor and a process for preparation thereof. The controlled release pharmaceutical composition comprises: a deposit-core comprising a selective serotonin reuptake inhibitor, one or more controlled release agent(s) and one or more pharmaceutically acceptable excipient(s), a support-platform applied to the deposit-core, a controlled release coating and, an immediate release coating comprising a selective serotonin reuptake inhibitor and one or more pharmaceutically acceptable excipient(s).
摘要翻译： 本发明提供一种包含选择性5-羟色胺再摄取抑制剂及其制备方法的控释药物组合物。 控释药物组合物包括：沉积物芯，其包含选择性5-羟色胺再摄取抑制剂，一种或多种控释剂和一种或多种药学上可接受的赋形剂，应用于沉积物核心的载体平台， 控制释放包衣和包含选择性5-羟色胺再摄取抑制剂和一种或多种药学上可接受的赋形剂的速释包衣。
-
公开(公告)号：US20130072512A1
公开(公告)日：2013-03-21
申请号：US13583769
申请日：2011-03-09
IPC分类号： A61K31/437 , A61P31/04
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
摘要翻译： 包含分散在悬浮液基中的利福昔明和一种或多种药学上可接受的添加剂的稳定的，掩味的即用型悬浮液。 还提供了制备利福昔明的稳定的，掩味的即用型悬浮液的方法，包括以下步骤：将利福昔明与悬浮液基体混合，并通过研磨悬浮液进一步调节利福昔明颗粒，获得均匀分散的利福昔明悬浮液 。
-
公开(公告)号：US20120219631A1
公开(公告)日：2012-08-30
申请号：US13505990
申请日：2010-11-03
IPC分类号： A61K31/165 , A61P25/08 , A61K9/14
摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
摘要翻译： 本发明提供了漆酶的改良释放制剂。 包含lacosamide和改性释放聚合物的本发明的改进释放制剂在至少12小时的时间段内提供了具有最小C max至C min峰到谷变化的lacosamide的改进释放。
-
公开(公告)号：US10786464B2
公开(公告)日：2020-09-29
申请号：US13505990
申请日：2010-11-03
摘要： The present invention provides a modified release formulation of lacosamide. The modified release formulation of the present invention comprising lacosamide and modified release polymer provides modified release of lacosamide with minimal Cmax to Cmin peak to trough variation over a period of at least 12 hrs.
-
公开(公告)号：US20110003837A1
公开(公告)日：2011-01-06
申请号：US12865448
申请日：2009-01-30
申请人： Sheetal KULKARNI , Srirupa DAS , Ashish Ashokrao DESHMUKH , Satish Kumar DALAL , Shirishkumar KULKARNI
发明人： Sheetal KULKARNI , Srirupa DAS , Ashish Ashokrao DESHMUKH , Satish Kumar DALAL , Shirishkumar KULKARNI
IPC分类号： A61K31/505 , A61P3/06
CPC分类号： A61K9/2054 , A61K9/205 , A61K31/22 , A61K31/505
摘要： Modified release formulations of HMG Co-A reductase inhibitors, which provide reduced incidence of rhabdomyolysis, renal toxicity and other side effects by increasing hepatic bioavailability and decreasing systemic availability upon oral administration. The modified release pharmaceutical formulation comprises a therapeutically effective amount of HMG CoA reductase inhibitor or a pharmaceutically acceptable salt(s), polymorph(s), solvate(s), hydrate(s), prodrug or metabolite thereof, one or more release modifying agent(s) and one or more pharmaceutically acceptable excipient(s), wherein the modified release formulation provides reduced incidence of adverse effects and improved efficacy when compared to the immediate release formulation upon oral administration.
摘要翻译： HMG Co-A还原酶抑制剂的调制释放制剂，通过增加肝脏生物利用度和降低口服给药时的全身可用性，提供横纹肌溶解发生率降低，肾毒性和其他副作用。 该改性释放药物制剂包含治疗有效量的HMG CoA还原酶抑制剂或其药学上可接受的盐，多晶型物，溶剂化物，水合物，前药或代谢物，一种或多种释放调节剂 和一种或多种药学上可接受的赋形剂，其中当与口服给药时的立即释放制剂相比时，所述改性释放制剂提供减少的不良反应发生率和改善的功效。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.011 秒)
